Summary The serum levels of CA 19-9 and carcinoembryonic antigen (CEA) were determined in 37 patients with benign colorectal diseases and in 111 patients with newly discovered colorectal carcinomas or clinically verified relapses. In cancer patients, the CA 19-9 level ranged from normal (0-37Uml-1) to 77,500Uml-P whereas all samples but one from patients with benign colorectal diseases had a normal value. CA 19-9 was increased in 46% and 45% of patients with an advanced (Dukes C or D) carcinoma or a verified recidive, respectively. Only one out of 26 patients (4%) with a localized (Dukes A or B) carcinoma displayed an elevated CA 19-9 level (>37Um.1-1). No clear correlation was found between the CA 19-9 and CEA levels. The sensitivity of the CA 19-9 test (36%) was poorer than that of the CEA assay (69%), but the new test was markedly more specific (97% vs 70%) than the CEA assay.
Carcinoembryonic antigen (CEA) was first considered as a specific marker for colonic cancer (Thomson et al., 1969) , but further studies on this antigen showed elevated levels in a large proportion of patients with various malignant and benign diseases (Zamcheck et al., 1972) . The present status of CEA in the diagnosis and follow-up of malignomas clearly indiaFtes that the CEA determination is a poor screening test for malignant diseases. Serial CEA monitoring, however, gives valuable information in the detection of residual or recurrent cancer (Cooper et al., 1979; Goldenberg, 1979) .
The CA 19-9 test is a new radioimmunoassay for the measurement of a carbohydrate determinant (sialylated lacto-N-Fucopentaose II) of a circulating antigen (Del Villano et al., 1983) . The assay employs a monoclonal antibody originally raised against a human colon carcinoma cell line (SW 1116) (Koprowski et al., 1979) . Elevated CA 19-9 levels have been found in the serum of patients with various gastro-intestinal carcinomas (Del Villano et al., 1983; Koprowski et al., 1981) and the results of Sears et al. (1982) indicate that the CA 19-9 antigen is a new marker which can help in the diagnosis and monitoring of colorectal carcinomas.
In this investigation, we have studied CA 19-9 and CEA levels in the serum of patients with a newly discovered, still untreated colorectal carcinoma and in operated patients with residual tumour or a clinically confirmed relapse. The main emphasis has been focused on the comparison of CA 19-9 and CEA values.
Materials and methods

Patients
A total of 111 patients with a histologically verified colorectal carcinoma and 37 patients with benign colorectal disease were included in this study. The benign diseases consisted of colorectal polyposis (14 patients), benign adenoma (8), diverticulosis (6), ulcerative colitis (8) Employing a cut-off value of 37Uml-1, 0.6% of normal blood bank donors have a higher concentration (Del Villano et al., 1983) .
Serum samples were stored at -20°C from 1-18 months before the CA 19-9 assay.
Results
The CA 19-9 antigen levels The CA 19-9 level was normal (0-37 U ml1) in all but one of the 37 patients with a benign colorectal disease ( Figure 1 ). In patients with a newly discovered colorectal cancer or a clinically verified relapse the CA 19-9 value ranged from normal to 77,500 U ml-I (Figure 1 (Figure 1 ).
Comparison of CEA and CA 19-9 levels No correlation between CEA and CA 19-9 levels was found (r2=0.0269), as summarized in Table I and Figure 2 . In benign diseases, CEA was elevated above the normal range (>2.5ngml-1) in 30% of the patients while an elevated CA 19-9 value was found in only 1/37 patients.
Eight patients (31%) with a localized carcinoma had an elevated CEA level. However, none of the Dukes A or B patients showed simultaneous elevation of CEA and CA 19-9 (Table I) . Both markers were, on the other hand, elevated in 42% of patients with a more advanced cancer (Dukes C or D). In this group, a pathological CEA value with a normal CA 19-9 concentration was found in 40% of the patients while the opposite was true in only 2/45 patients (4%). The CEA level was normal in 8 patients (20%) and in clinically verified relapse. One of these patients had a slightly elevated CA 19-9 value (50Uml-1) ( Table I ). In operated patients with a slightly (2,5-l0ngml-1) or clearly (>10ngml-1) elevated CEA level, a pathological CA 19-9 concentration was found in 36% and in 50% of the cases, respectively (Figure 1 ).
Assay parameters
Assay parameters were determined as shown in Table II . Sensitivity of the CEA test was 69%, for the CA 19-9 assay 36% and for the combination of both determinations 73%. The best specificity was obtained by the CA 19-9 quantitation (97%)
. (Zamcheck et al., 1972; Cooper et al., 1979; Goldenberg, 1979 This would, however, decrease the specificity and not significantly increase the detection of small localized tumours, as can be seen in Figure 1 . Using a cut-off level of 37Uml-1, the specificity (97%) and predictive value (98%) of the CA 19-9 assay were far better than those of the CEA test. We found a slightly elevated CA 19-9 level in only one patient with colonic pQlyposis whereas elevated CEA values were found in 30% of the patients with benign diseases. This finding is in good agreement with the observation that CEA can be found in the normal colorectal mucosa or in benign tumours (Martin & Martin, 1972; Fritsche & Mach, 1977) whereas Atkinson et al. (1982) failed to demonstrate histochemically any CA 19-9 antigen in the normal colon tissue. The expression of the CA 19-9 antigen is, however, not specific for colon cancer. Patients with hepatopathies combined with elevated serum bilirubin levels can have increased CA 19-9 concentrations (Jalanko et al. In press). Elevated serum antigen levels can be found in patients with various gastro-intestinal cancers such as pancreatic, biliary tract and gastric carcinomas, and also in some patients with benign upper gastrointestinal diseases (Del Villano et al., 1983) . The CA 19-9 is also found histochemically in corresponding normal and malignant tissues (Atkinson et al., 1982) . Sears et al. (1982) have previously performed a longitudinal follow-up study of patients who had their primary colorectal cancer surgically removed. The cancer recurred in 10 of their patients and in 8 of these the serum CA 19-9 assay predicted the recurrence 3-18 months prior to the development of any clinical or laboratory sign. We studied CA 19-9 levels in 40 patients with a recurrent colorectal cancer and found elevated CA 19-9 values in 45% of them. The difference in the percentages of elevated CA 19-9 levels between our patients and those of Sears et al. (80%) may be due to the fact that 9/10 patients in their series had increased CA 19-9 concentration already preoperatively whereas our patients represented a random population with regard to CA 19-9 values. No clear-cut correlation was observed between CA 19-9 and CEA levels. Because of the poor sensitivity neither of these markers are optimal for screening of colorectal carcinomas. In order to exclude minor CEA variations not due to tumours the CEA concentration 5ngml-1 has been accepted in many laboratories as the cut-off point for the CEA determination. In our data, this cut-off level results only in minor changes in the assay parameters for the CEA test and, consequently, has no effect on the comparison of the CEA and CA determinations. The differential expression of the CA 19-9 antigen and the high predictive value for the CA 19-9 assay (98%), however, suggest that monitoring of CA 19-9 levels may give additional information to that obtained by the CEA determination. In this sense, the CA 19-9 antigen can be a useful additional marker in the diagnosis and follow-up of colorectal cancers.
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